The 7 analysts offering 12-month price forecasts for Aeglea Bio Therapeutics Inc have a median target of 3.00, with a high estimate of 8.00 and a low estimate of 1.00. The median estimate represents a +487.08% increase from the last price of 0.51.
The current consensus among 8 polled investment analysts is to Buy stock in Aeglea Bio Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.31
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.